biostudies-literatureUnknown393(9)Molderings GJFörderclub Mastzellforschung e.V.Omalizumab is an effective therapeutic humanized murine IgE antibody in many cases of primary systemic mast cell activation disease (MCAD). The present study should enable the clinician to recognize when treatment of MCAD with omalizumab is contraindicated because of the potential risk of severe serum sickness and to report our successful therapeutic strategy for such adverse event (AE). Our clinical observations, a review of the literature including the event reports in the FDA AE Reporting System, the European Medicines Agency Eudra-Vigilance databases (preferred search terms: omalizumab, Xolair®, and serum sickness) and information from the manufacturer's Novartis database were used. Omalizumab therapy may be more likely to cause serum sickness than previously thought. In patients with Naunyn-Schmiedeberg's archives of pharmacology1573-1580https://www.ebi.ac.uk/biostudies/studies/S-EPMC7419348biostudies-literatureAdrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.PMC7419348Tridente GDumoulin FLRaithel MKlingmuller DBarion RHertfelder HJTextor JMucke MAfrin LBMolderings GJQagish GJHomann JSido BWeinstock LBSchafer VSBerdel DfalseAdrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.Omalizumab is an effective therapeutic humanized murine IgE antibody in many cases of primary systemic mast cell activation disease (MCAD). The present study should enable the clinician to recognize when treatment of MCAD with omalizumab is contraindicated because of the potential risk of severe serum sickness and to report our successful therapeutic strategy for such adverse event (AE). Our clinical observations, a review of the literature including the event reports in the FDA AE Reporting System, the European Medicines Agency Eudra-Vigilance databases (preferred search terms: omalizumab, Xolair®, and serum sickness) and information from the manufacturer's Novartis database were used. Omalizumab therapy may be more likely to cause serum sickness than previously thought. In patients with 2020-01-01T00:00:00Z2020 Sep2026-05-05T06:42:00.549Z2020-08-23T07:14:09ZS-EPMC74193483237777010.1007/s00210-020-01886-2